HLN · Pharma and healthcare · one day
Haleon (HLN): news on Friday 30 October 2026
News from the 24 hours to Friday morning, 30 October 2026.
Tone of the day
−10.0strongly negative
−10.0
Relevant headlines70
Stories10
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was dominated by Haleon's third-quarter sales shortfall and a reduced 2026 growth outlook, attributed to poor sales of cold and flu remedies and problems in China, which drove the shares down sharply. A £500 million buyback and a chief executive memo cautioning about tough decisions did little to temper the negative tone.
What drove it
- Q3 sales miss and guidance cut
- share price plunge
- £500m buyback
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 24 Oct | +2.3 | 5 |
| Sun 25 Oct | +5.7 | 3 |
| Mon 26 Oct | −1.2 | 3 |
| Tue 27 Oct | +4.2 | 2 |
| Wed 28 Oct | +1.3 | 5 |
| Thu 29 Oct | +5.7 | 5 |
| Fri 30 Oct | −10.0 | 70 |
10 stories · 70 headlines · strongest first
Pharma and healthcare on 30 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Haleon lowers its 2026 growth outlook following soft third quarter −10.050 headlines today · Haleon posted third-quarter growth of 2.6% and lowered its full-year organic growth outlook to around 2.5%, citing weak demand in the cold and flu category and disruption in China, and its shares dropped steeply. | ||
| −10.0 | Sales miss forces cut, analysts see margin reset | |
| −10.0 | Shares fall on soft seasonal remedy demand | |
| −10.0 | Weak demand and China problems force lower outlook | |
| −10.0 | Biggest one-day share fall since market debut | |
| −10.0 | Large share price drop on index | |
| −10.0 | Shares reach lowest level in a year | |
| −10.0 | Sharp share drop after weaker quarter and lowered growth view | |
| −10.0 | Shares collapse on soft seasonal demand | |
| −10.0 | Heavy share price fall dominates market wrap | |
| −10.0 | Shares tumble after lowered outlook | |
| −10.0 | Shares crash after quarterly update | |
| −10.0 | Quarter missed, guidance lowered, recovery pushed back | |
| −10.0 | Shares plunge after guidance reduced | |
| −10.0 | Quarterly sales shortfall and weaker growth outlook | |
| −10.0 | Shares plunge despite repurchase launch | |
| −10.0 | Shares fall as targets lowered on weak demand | |
| −10.0 | Forecasts cut after poor seasonal sales | |
| −10.0 | Explains steep share price fall | |
| −10.0 | Among biggest fallers on the index | |
| −10.0 | Shares slump as revenue target reduced | |
| −10.0 | Poor seasonal sales hit forecasts | |
| −10.0 | Slower growth and revised targets hit shares | |
| −10.0 | Premarket drop after quarterly growth shortfall | |
| −10.0 | Annual sales outlook reduced on weaker illness season | |
| −10.0 | Weak demand and China supplement ban reduce growth view | |
| −10.0 | Named as a loser on outlook downgrade | |
| −10.0 | Full-year outlook lowered | |
| −10.0 | Revenue outlook lowered and Brazil changes sped up | |
| −10.0 | Annual revenue guidance cut, shares fall | |
| −10.0 | Outlook reduction drove shares lower | |
| −10.0 | Weak flu season and China disruption cut forecast | |
| −10.0 | Second consumer health firm trimming guidance, sector pressure | |
| −10.0 | Quarter fell short of own target, buyback added | |
| −10.0 | Shares weak in morning market report | |
| −10.0 | Growth below expectations and guidance lowered | |
| −10.0 | Weak seasonal demand hurts at bad moment | |
| −10.0 | Annual organic revenue forecast reduced | |
| −10.0 | Revenue growth outlook lowered on weak remedy demand | |
| −10.0 | Shares hit low after downgrade despite repurchase | |
| −10.0 | Growth outlook lowered to 2.5 percent | |
| −9.2 | Columnist sees need for tough remedies after weak sales | |
| −9.2 | Growth forecast lowered, buyback announced | |
| −9.2 | Growth view trimmed on weak demand, buyback offsets | |
| −9.2 | Lower growth forecast partly offset by share repurchase | |
| −9.2 | Lowered organic growth expectation for the year | |
| −8.3 | Market news roundup including its share fall | |
| −8.3 | Quarterly revenue rose but full-year outlook lowered | |
| −8.3 | Quarterly growth, lowered annual view, buyback summary | |
| −6.7 | Earnings call recap following weak quarter | |
| −2.5 | Modest quarterly growth with buyback announced | |
| Haleon chief executive tells staff hard choices lie ahead −10.05 headlines today · A memo reported by Reuters shows Haleon's chief executive warning staff of difficult choices after the sales miss. | ||
| −10.0 | CEO warns staff of tough choices after sales miss | |
| −10.0 | CEO warns staff of tough choices after sales miss | |
| −10.0 | CEO warns of tough decisions after sales shortfall | |
| −10.0 | CEO warns of tough decisions after sales shortfall | |
| −10.0 | CEO signals tough decisions in staff note | |
| Haleon starts £500m share buyback +1.75 headlines today · Haleon announced the start of a £500m share buyback programme. | ||
| +1.7 | Share repurchase programme launched | |
| +1.7 | Buyback start, overshadowed by quarterly update | |
| +1.7 | Formal notice of buyback start | |
| +1.7 | Share repurchase programme begins | |
| +1.7 | Buyback launched, mildly supportive for shareholders | |
| Haleon share price chatter −0.63 headlines today · Trading-focused pieces describe Haleon's share movement and momentum. | ||
| −8.3 | Technical chart weakness in the shares | |
| +3.3 | Stock-pick commentary on modest strength | |
| +3.3 | Stock-pick commentary on defensive appeal | |
| Haleon Pakistan begins local Panadol 500mg manufacturing +2.52 headlines today · Haleon started making Panadol 500mg tablets locally in Jamshoro. | ||
| +2.5 | Local production start in Pakistan, minor operational expansion | |
| +2.5 | Pakistan unit begins domestic tablet production, small positive | |
| Haleon valuation and growth commentary −6.71 headline today · Stockopedia comments on Haleon's revenue growth and valuation. | ||
| −6.7 | Analyst sees sluggish growth and unexciting valuation | |
| Haleon 12-month price target lowered to $11.03 −5.01 headline today · A 12-month price target for Haleon was lowered, implying 10% upside. | ||
| −5.0 | Analyst target lowered, though some upside remains | |
| Haleon Korea cleans Sungkyunkwan heritage buildings +3.31 headline today · Haleon Korea took part in a heritage preservation activity at Sungkyunkwan. | ||
| +3.3 | Korean unit's heritage conservation effort helps reputation | |
| Haleon names talent acquisition director for Greater China 0.01 headline today · Haleon has picked Lico Qiu to direct talent acquisition in Hong Kong and Greater China. | ||
| 0.0 | Routine senior hire in China talent team | |
| Haleon compared with Asahi Glass as value stock 0.01 headline today · A piece compares Haleon with ASAIY as a value stock. | ||
| 0.0 | Valuation comparison, no clear direction | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated Haleon: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.